87776-76-9

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dihydro-5-benzofuranethanol is used as a key intermediate in the synthesis of Darifenacin (D193400, HBr), a medication specifically designed to treat urinary incontinence. 2,3-Dihydro-5-benzofuranethanol's unique structure allows it to effectively block the M3 muscarinic acetylcholine receptor, which is responsible for controlling the contraction of the bladder muscles. By inhibiting this receptor, Darifenacin helps to reduce the frequency and urgency of urination, providing relief to patients suffering from urinary incontinence.
In addition to its role in the synthesis of Darifenacin, 2,3-Dihydro-5-benzofuranethanol may also be utilized in the development of other pharmaceuticals with different therapeutic targets. Its unique chemical structure makes it a valuable building block for the creation of new drugs, potentially leading to the discovery of novel treatments for a wide range of medical conditions.

InChI:InChI=1/C10H12O2/c11-5-3-8-1-2-10-9(7-8)4-6-12-10/h1-2,7,11H,3-6H2

Upstream product

• 69999-16-2 2,3-dihydrobenzofuran-5-acetic acid 
• 496-16-2 2.3-dihydrobenzofuran 
• 79002-49-6 ethyl 2( 2,3-dihydro-1-benzofuran-5-yl)oxoacetate 
• 156-38-7 4-hydroxyphenylacetate 
• 121638-36-6 methyl 2-(benzofuran-5-yl)acetate 
• 142935-60-2 benzofuran-5-yl-acetic acid 
• 69999-18-4 ethyl 2,3-dihydrobenzofuran-5-ylacetate 
• 943589-92-2 2-(2,3-dihydrobenzofuran-5-yl)acetaldehyde bisulfitic complex 
• 155852-41-8 methyl 2-(2,3-dihydrobenzofuran-5-yl)acetate 

Downstream Products

• 127264-14-6 2,3-dihydro-5-(2-bromoethyl)benzofuran 
• 79679-49-5 2-(2,3-dihidrobenzofuran-5-yl)ethyl tosylate 
• 1423014-75-8 C₂₃H₂₅NO₃ 
• 133099-07-7 (S)-darifenacin hydrobromide 
• 943034-50-2 2-(2,3-dihydrobenzofuran-5-yl)ethylchloride 

Relevant academic research and scientific papers

Darifenacin intermediate 2, 3 - dihydro - 5 - benzofuran acetic acid preparation new method of (by machine translation)

The invention relates to a darifenacin intermediate - 2, 3 - dihydro - 5 - benzofuran acetic acid. By the P-hydroxy-acetic acid and bromo acetaldehyde acetal as the starting material, the presence of O - alkylation reaction under a condition of the corresponding ether compound; then by esterification reaction to obtain the corresponding ester; in PPA (poly phosphoric acid) under the action of the, cyclization to obtain 2, 3 - benzofuran - 5 - acetate; 2, 3 - benzofuran - 5 - acetic acid layer which hydrolysis, to acidify the corresponding carboxylic acid; obtained by catalytic hydrogenation of 2, 3 - dihydro - 5 - benzofuran acetic acid; or the first 2, 3 - benzofuran - 5 - acetate obtained by catalytic hydrogenation of 2, 3 - dihydro - 5 - benzofuran acetic acid esters; and hydrolyzed, acidified to obtain 2, 3 - dihydro - 5 - benzofuran acetic acid. The method of the invention by simple and safe, each reaction raw materials are cheap and easy to obtain, the reaction yield is high, and is particularly suitable for industrial production of 2, 3 - dihydro - 5 - benzofuran acetic acid. (by machine translation)

Novel preparation method of darifenacin intermediate 2,3-dihydro-5-benzofuran acetic acid

The invention relates to a novel preparation method of a darifenacin intermediate 2,3-dihydro-5-benzofuran acetic acid. The method comprises the following steps: by taking 2,3-dihydrobenzofuran as aninitial raw material in the presence of a Lewis acid, carrying out a Friedel-Crafts acylation reaction with ethyl oxalyl monochloride so as to obtain a corresponding acyl compound; hydrolyzing to obtain alpha-ketonic acid sodium salt; reducing carbonyl into methylene by utilizing a Wolff-Kishner-HuangMinlong reaction, and acidizing, thereby obtaining the 2,3-dihydro-5-benzofuran acetic acid. The method disclosed by the invention is simple, convenient and safe, cheap and readily available in reactive raw materials and high in reaction yield and is particularly suitable for industrialized production of the 2,3-dihydro-5-benzofuran acetic acid.

Highly sulphated cellulose: a versatile, reusable and selective desilylating agent for deprotection of alcoholic TBDMS ethers

A mild, efficient and rapid protocol was developed for the deprotection of alcoholic TBDMS ethers using a recyclable, eco-friendly highly sulphated cellulose sulphate acid catalyst in methanol. This acid catalyst selectively cleaves alcoholic TBDMS ethers in bis-TBDMS ethers containing both alcoholic and phenolic TBDMS ether moieties.

SUBSTITUTED PYRROLIDINES

Disclosed herein are substituted pyrrolidine-based muscarinic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

OXAZOLE AND THIAZOLE DERIVATIVES AND THEIR USES

A quaternary ammonium compound of formula (I) having M3 receptor antagonist activity; a composition comprising such a compound; the use of such a compound in therapy (such as asthma or COPD); and a method of treating a patient with such a compound.

PROCESSES FOR PREPARING DARIFENACIN HYDROBROMIDE

The invention encompasses processes for the preparation of darifenacin hydrobromide.

HIV-1 VIRION MATURATION INHIBITORS, COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts and solvates thereof, which are useful as inhibitors of human immunodeficiency virus (HIV) and are also useful for the treatment of HIV infections in HIV- infected mammals, including humans. The present invention also provides pharmaceutical compositions comprising compounds of Formula I1 II, III or IV, and their pharmaceutically acceptable salts and solvates.

MUSCARINIC RECEPTOR ANTAGONISTS

The invetion is a method of treating irritable bowel syndrome with a compound selected from the formula STR1 wherein R, R 1, m, n p are as defined in the specification, or a pharmaceutically acceptable salt thereof.

ANTICHOLINERGIC AGENTS

Selective muscarinic receptor antagonists of formula (I): STR1 wherein R 1 and R 2 are both optionally substituted phenyl, the broken line is an optional bond, X is > COH--, > SiOH--or CH--when the double bond is absent or is > C= when the double bond is present, X being attached to a carbon atom of A, A is selected from certain piperidine and pyrrolidine groups, n is 1 to 3 and R 3 is optionally substituted phenyl or thienyl, pyridyl or pyrazinyl.